Cargando…

Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective

BACKGROUND: Adaptive designs offer added flexibility in the execution of clinical trials, including the possibilities of allocating more patients to the treatments that turned out more successful, and early stopping due to either declared success or futility. Commonly applied adaptive designs, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Arjas, Elja, Gasbarra, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858379/
https://www.ncbi.nlm.nih.gov/pubmed/35184731
http://dx.doi.org/10.1186/s12874-022-01526-8
_version_ 1784654228467220480
author Arjas, Elja
Gasbarra, Dario
author_facet Arjas, Elja
Gasbarra, Dario
author_sort Arjas, Elja
collection PubMed
description BACKGROUND: Adaptive designs offer added flexibility in the execution of clinical trials, including the possibilities of allocating more patients to the treatments that turned out more successful, and early stopping due to either declared success or futility. Commonly applied adaptive designs, such as group sequential methods, are based on the frequentist paradigm and on ideas from statistical significance testing. Interim checks during the trial will have the effect of inflating the Type 1 error rate, or, if this rate is controlled and kept fixed, lowering the power. RESULTS: The purpose of the paper is to demonstrate the usefulness of the Bayesian approach in the design and in the actual running of randomized clinical trials during phase II and III. This approach is based on comparing the performance of the different treatment arms in terms of the respective joint posterior probabilities evaluated sequentially from the accruing outcome data, and then taking a control action if such posterior probabilities fall below a pre-specified critical threshold value. Two types of actions are considered: treatment allocation, putting on hold at least temporarily further accrual of patients to a treatment arm, and treatment selection, removing an arm from the trial permanently. The main development in the paper is in terms of binary outcomes, but extensions for handling time-to-event data, including data from vaccine trials, are also discussed. The performance of the proposed methodology is tested in extensive simulation experiments, with numerical results and graphical illustrations documented in a Supplement to the main text. As a companion to this paper, an implementation of the methods is provided in the form of a freely available R package ’barts’. CONCLUSION: The proposed methods for trial design provide an attractive alternative to their frequentist counterparts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at (10.1186/s12874-022-01526-8).
format Online
Article
Text
id pubmed-8858379
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88583792022-02-22 Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective Arjas, Elja Gasbarra, Dario BMC Med Res Methodol Research BACKGROUND: Adaptive designs offer added flexibility in the execution of clinical trials, including the possibilities of allocating more patients to the treatments that turned out more successful, and early stopping due to either declared success or futility. Commonly applied adaptive designs, such as group sequential methods, are based on the frequentist paradigm and on ideas from statistical significance testing. Interim checks during the trial will have the effect of inflating the Type 1 error rate, or, if this rate is controlled and kept fixed, lowering the power. RESULTS: The purpose of the paper is to demonstrate the usefulness of the Bayesian approach in the design and in the actual running of randomized clinical trials during phase II and III. This approach is based on comparing the performance of the different treatment arms in terms of the respective joint posterior probabilities evaluated sequentially from the accruing outcome data, and then taking a control action if such posterior probabilities fall below a pre-specified critical threshold value. Two types of actions are considered: treatment allocation, putting on hold at least temporarily further accrual of patients to a treatment arm, and treatment selection, removing an arm from the trial permanently. The main development in the paper is in terms of binary outcomes, but extensions for handling time-to-event data, including data from vaccine trials, are also discussed. The performance of the proposed methodology is tested in extensive simulation experiments, with numerical results and graphical illustrations documented in a Supplement to the main text. As a companion to this paper, an implementation of the methods is provided in the form of a freely available R package ’barts’. CONCLUSION: The proposed methods for trial design provide an attractive alternative to their frequentist counterparts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at (10.1186/s12874-022-01526-8). BioMed Central 2022-02-20 /pmc/articles/PMC8858379/ /pubmed/35184731 http://dx.doi.org/10.1186/s12874-022-01526-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Arjas, Elja
Gasbarra, Dario
Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective
title Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective
title_full Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective
title_fullStr Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective
title_full_unstemmed Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective
title_short Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective
title_sort adaptive treatment allocation and selection in multi-arm clinical trials: a bayesian perspective
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858379/
https://www.ncbi.nlm.nih.gov/pubmed/35184731
http://dx.doi.org/10.1186/s12874-022-01526-8
work_keys_str_mv AT arjaselja adaptivetreatmentallocationandselectioninmultiarmclinicaltrialsabayesianperspective
AT gasbarradario adaptivetreatmentallocationandselectioninmultiarmclinicaltrialsabayesianperspective